<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1207</ReferenceId>
        <DateLastUpdated>2018-09-17-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12052563</PubmedId>
            <Abstract>The outer membrane protein F gene (oprF) of Pseudomonas aeruginosa was recently shown by us to protect mice from P. aeruginosa chronic pulmonary infection when used as a DNA vaccine administered by three biolistic (gene gun) intradermal inoculations given at 2-week intervals. In the present study, we used two different strategies to improve the protective efficacy of the DNA vaccine. In the first strategy, mice were primed with two biolistic intradermal inoculations with the oprF vaccine and then were given a final intramuscular booster immunization containing either a synthetic peptide-keyhole limpet hemocyanin (KLH) conjugate or a chimeric influenza virus. Both the synthetic peptide conjugate and the chimeric virus contained peptide 10, a previously identified immunoprotective epitope of protein F. The second strategy involved the addition of a second outer membrane protein to the vaccine. DNA encoding a fusion protein comprised of the C-terminal half of protein F fused to OprI was administered by three biolistic intradermal inoculations. Challenge with P. aeruginosa in a chronic pulmonary infection model demonstrated that boosting with the chimeric virus (but not with peptide-KLH) or adding oprI to the DNA vaccine significantly enhanced protection as compared to that afforded by the oprF vaccine given alone. Thus, both strategies appear to augment the protection afforded by an oprF-only DNA vaccine.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>89-99</ArticlePages>
            <ArticleTitle>Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Price</LastName>
                    <ForeName>Brian M</ForeName>
                </Author>
                <Author>
                    <LastName>Barten Legutki</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Galloway</LastName>
                    <ForeName>Darrell R</ForeName>
                </Author>
                <Author>
                    <LastName>von Specht</LastName>
                    <ForeName>Bernd Ulrich</ForeName>
                </Author>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>Linda B</ForeName>
                </Author>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>Harry E</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Staczek</LastName>
                    <ForeName>John</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology, The Ohio State University, 484 West 12th Ave., Columbus, OH 43210-1292, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Bacterial Vaccines;Opsonin Proteins;Peptides;Porins;Recombinant Fusion Proteins;Vaccines, DNA;Hemocyanins;keyhole-limpet hemocyanin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Bacterial(blood); Bacterial Vaccines(administration &amp; dosage; immunology); Chronic Disease; Disease Models, Animal; Female; Hemocyanins(genetics; immunology); Humans; Immunization Schedule; Immunization, Secondary; Lung Diseases(microbiology; prevention &amp; control); Mice; Mice, Inbred BALB C; Opsonin Proteins(metabolism); Orthomyxoviridae(genetics; immunology; metabolism); Peptides(chemical synthesis; genetics; immunology); Porins(chemistry; genetics; immunology; metabolism); Pseudomonas Infections(microbiology; prevention &amp; control); Pseudomonas aeruginosa(genetics; immunology); Recombinant Fusion Proteins(immunology); Vaccines, DNA(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>33</Volume>
                <Issue>2</Issue>
                <Title>FEMS immunology and medical microbiology</Title>
                <Issn>1574-695X</Issn>
                <MedlineTa>FEMS Immunol Med Microbiol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Peptide 10</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                        <StartingPosition>329</StartingPosition>
                        <EndingPosition>342</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_250468.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>287</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>43317</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>14</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>17678</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Sex>F</Sex>
                                <Age>5 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>NP_250468.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>287</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Other</Route>
                                <DoseSchedule>3 doses of 2 ug plasmid coated onto 1 um gold beads</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Innoculation (14-day intervals) is intra-abdominal via biolistic particle injection. Various combinations of primary/booster regimens were used: 1) three innoculations of plasmid (encoding the source protein), 2)   two innoculations of the plasmid (encoding the source protein) plus i.m. booster with Peptide 10-KLH, 3) two innoculations of the plasmid (encoding the source protein) plus i.m. booster with chimeric HG10-11 virus expressing Peptide 10, and 4) three innoculations of a plasmid construct containing parts of oprF and oprI.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Sera were collected from 2 immunized mice on day 28 and from 3 mice on day 42 and  pooled for antibody detection. In the various immunization protocols used, sera reacted to synthetic peptide 10 (the assay antigen).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Peptide 10</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>342</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_250468.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>287</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

